secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celularity Inc (CELU)
CIK:        0001752828
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001493152-25-007986
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celularity enters manufacturing collaboration with BlueSphere Bio for AML cell therapy
--------------------------------------------------------------------------------

- Master Services Collaboration Agreement to manufacture BlueSphere's TCR T cell therapies for AML.
- Work to be performed at Celularity's 37,000 sq ft Florham Park cGMP facility; dedicated staff and small portion of footprint used.
- BlueSphere's second cell therapy product for AML will be produced; BlueSphere retains oversight.
- Celularity CEO highlights revenue potential of leveraging manufacturing infrastructure for third-party clients.
- BlueSphere expects to dose first patient in TCX-101 program in 1H2025 and file IND for TCX-102 in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1752828/000149315225007986/0001493152-25-007986-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1752828/000149315225007986/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-007986

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer